ArticlePreventive medicine reports2017
Recent trends in the prevalence of low-dose aspirin use for primary and secondary prevention of cardiovascular disease in the United States, 2012-2015.
Article in Preventive medicine reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 1 synthesis or guideline pooled it, 107 citations in OpenAlex.
- Effect of low-dose aspirin on health outcomes: An umbrella review of systematic reviews and meta-analyses.British journal of clinical pharmacology · 2020Pooled it
- Randomised clinical study: oral aspirin 325 mg daily vs placebo alters gut microbial composition and bacterial taxa associated with colorectal cancer risk.Alimentary pharmacology & therapeutics · 2020Trial
- Omega-3 Polyunsaturated Fatty Acids EPA and DHA as an Adjunct to Non-Surgical Treatment of Periodontitis: A Randomized Clinical Trial.Nutrients · 2020Trial
- Associations between use of aspirin and magnetic resonance imaging-derived liver fat and fibroinflammation.Diabetes, obesity & metabolism · 2026Article
- Chemoprevention of Colorectal Cancer-With Emphasis on Low-Dose Aspirin and Anticoagulants.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Aspirin does not confer protection against major ischemic vascular events in patients diagnosed with rheumatoid arthritis.The Journal of international medical research · 2025Article
- Guideline concordance of aspirin use for primary prevention in adult outpatients.Blood advances · 2024Article
- Effect of Low-Dose Aspirin on the Elderly.Cureus · 2024Review
- Association of low-dose aspirin use for primary prevention with self-reported kidney stones prevalence: a cross-sectional study.World journal of urology · 2023Article
- Exploring the Association between Low-dose Aspirin Intake and Hyperuricemia in Individuals over 40: A Cross-Sectional Study using NHANES Data (2011-2018).Medical science monitor : international medical journal of experimental and clinical research · 2023Article
- Trends in Provision of Medications and Lifestyle Counseling in Ambulatory Settings by Gender and Race for Patients With Atherosclerotic Cardiovascular Disease, 2006-2016.JAMA network open · 2023Article
- A survey of internists' recommendations for aspirin in older adults and barriers to evidence-based use.Journal of thrombosis and thrombolysis · 2022Article
- Assessment of an Intervention to Reduce Aspirin Prescribing for Patients Receiving Warfarin for Anticoagulation.JAMA network open · 2022Observational
- Preoperative Use of Aspirin in Total Knee Arthroplasty: Safe or Not?Orthopaedic surgery · 2022Article
- Retrospective Cohort Analysis of Aspirin Use and Venous Thromboembolism in Patients with Pancreatic Cancer and an Indwelling Central Venous Catheter.TH open : companion journal to thrombosis and haemostasis · 2022Article
- Aspirin Use among Saudi Adults: The Prevalence and Users' Characteristics.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2022Article
- Trends in the use of oral anticoagulants, antiplatelets and statins in four European countries: a population-based study.European journal of clinical pharmacology · 2022Article
- Analgesic Use and Circulating Estrogens, Androgens, and Their Metabolites in the Women's Health Initiative Observational Study.Cancer prevention research (Philadelphia, Pa.) · 2022Observational
- Aspirin for cardiovascular disease prevention among adults in the United States: Trends, prevalence, and participant characteristics associated with use.American journal of preventive cardiology · 2021Article
- Effects of Arachidonic Acid Metabolites on Cardiovascular Health and Disease.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aspirin therapy has been shown to be an effective prevention measure to reduce the risk of new or recurring cardiovascular events. The aim of this study was to provide an epidemiological analysis of low-dose aspirin use for primary and secondary CVD prevention from 2012 to 2015. Estimates of self-reported low-dose aspirin use for primary and secondary CVD prevention were obtained from the National Health Interview Survey for the years 2012-2015. Temporal changes in the prevalence of aspirin use for primary and secondary CVD prevention were assessed using logistic regression. During 2012-2015, 23.3% of respondents self-reported as taking aspirin for primary CVD prevention, decreasing from 23.7% in 2012 to 21.8% in 2015. Also during this period, 8.4% self-reported as taking aspirin for secondary CVD prevention, decreasing from 8.9% in 2012 to 8.2% in 2015. Overall, the prevalence of aspirin use for CVD prevention declined from 32.6% in 2012 to 30.0% in 2015. This study shows that over 30% of the adult population self-reports as taking low-dose aspirin for primary or secondary CVD prevention. Despite the decline in this prevalence over the previous four years, aspirin therapy remains a highly-utilized means of preventing CVD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.